
Share
A nurse practitioner-owned clinic network just landed a Series A from Kairos and Lerer Hippeau. The bigger bet: proving that NP-led, AI-supported primary care can outperform on cost and outcomes at scale.
Duet, a nurse practitioner-owned primary care network, has raised $15 million in Series A funding to expand its clinic footprint and deepen its insurer partnerships. Kairos led the round, with participation from Lerer Hippeau, bringing the company's total funding to $22.5 million.
The thesis behind the check is straightforward: primary care delivered by nurse practitioners, backed by AI tooling that handles administrative drag, can lower costs for payers while improving outcomes for patients. Kairos co-founder and co-CEO Alex Fiance called Duet "one of those rare businesses where everybody wins," pointing to a model that reaches underserved patients, turns clinicians into business owners, and reduces downstream costs by catching problems early.
Duet says it is now the largest network of independent NP-owned primary care practices in the country, working with more than 130 clinics across 21 states. The company helps those practices secure reimbursement through partnerships with major insurers including Anthem, Cigna and Centene, a function that matters more than it might sound. Independent practices often lack the scale to negotiate favorable terms or navigate value-based contracts on their own.
Founder and CEO Jonathan Goldberg described Duet's platform as a combination of practice advisors and AI-powered tools designed to free up NP time for actual patient care. The system flags patients drifting out of care and gets them rescheduled. It also compiles patient data ahead of visits so clinicians know what to prioritize, and it extends monitoring into the home through remote technology for patients who need closer attention.
"There's a lot stacked against small practices," Goldberg said. "Our mission is to help NPs show up for people that the system has overlooked."
The clinical numbers Duet is citing are notable, though they come from the company itself rather than independent audit. Patients across roughly 400,000 annual visits gave the network a Net Promoter Score of 92, an unusually high figure for a healthcare provider. Practices that join Duet reportedly see preventive screenings for breast and colon cancer rise 30%, while emergency room visits fall 20%. The company also says it re-engages 25% of previously unengaged patients, a cohort that tends to generate higher downstream costs when left untreated.
These are the kinds of metrics that matter most to payers evaluating value-based contracts. Lower ER utilization and higher screening rates translate directly into reduced claims spend, which is presumably why insurers have been willing to structure compensation arrangements around Duet's network rather than standard fee-for-service terms.

Goldberg said the fresh capital will go toward three priorities: onboarding more clinics, deepening value-based care partnerships with insurers, and expanding the engineering team. The company is also launching an accelerator program in 2027 aimed at helping newly affiliated clinics get up to speed quickly.
The more ambitious announcement tucked into this round is Duet's plan to launch the first-ever NP-led Medicare Accountable Care Organization in 2027. Under the model, nurse practitioners will design and govern the ACO themselves, a structural choice Goldberg says preserves practice autonomy while giving owners access to the technology and resources needed to strengthen care delivery.
"NPs already practice prevention first, and this gives them a way to be recognized for it," Goldberg said.
Medicare ACOs reward participants for reducing costs while hitting quality benchmarks, and most existing ACOs are physician-led or hospital-affiliated. An NP-governed structure would be a meaningful departure, and if Duet can demonstrate the shared savings that value-based contracts are designed to produce, it could open a template other NP networks look to replicate.
Duet's raise lands in a broader climate of healthcare AI investment that shows no sign of slowing. Norwest Venture Partners closed a $4 billion fund this month, the largest in its 65-year history, with healthcare AI among its named priorities. The firm has recently backed Vitalize Care's AI-powered hospital staffing platform and co-led a $150 million round for Matchpoint Therapeutics. Separately, Oura's planned $625 million acquisition of AI virtual primary care company Counsel Health signals continued consolidation appetite in the space. Capital is clearly available for companies that can pair clinical delivery with defensible technology, and Duet's round, while modest next to those figures, fits the same pattern.
Duet's $15 million Series A is small by healthcare AI standards, but the strategic logic is sound: independent NP practices face real structural disadvantages in negotiating with payers and managing administrative burden, and a network model with embedded technology addresses both. The self-reported clinical metrics, a 92 NPS and meaningful drops in ER utilization, are the kind of evidence payers want before expanding value-based arrangements, though investors should watch for third-party validation as the network scales past 130 clinics.
The bigger test comes in 2027, when Duet's NP-led Medicare ACO launches. Shared savings programs live or die on actuarial performance, not press releases, and Duet will need to show that its preventive-care model generates measurable reductions in total cost of care under Medicare's benchmarking rules. If it does, the company has a credible path to becoming the reference model for NP-governed value-based care, a niche within primary care that remains largely unclaimed. If it falls short, the company will face the same cost pressures that have challenged other provider-led ACOs. Either outcome will be instructive for a sector still working out which care delivery models can actually bend the cost curve.
Tags
Original Sources
Duet nabs $15M series A, plans to launch first NP-led ACO in 2027
↗ https://www.fiercehealthcare.com/finance/duet-nabs-15m-series-plans-launch-first-np-led-aco-2027
About the author
Marcus began tracking AI's market implications in 2016, noticing AI-related patent filings accelerating ahead of earnings upgrades before most of the sell-side had caught on. A former fixed-income quantitative analyst, he spent two decades building models that priced risk across emerging markets before pivoting to cover the economic impact of AI full-time. His writing translates opaque technical developments into clear risk/reward terms — and he's rarely diplomatic about the gap between AI valuations and underlying fundamentals. He believes most market participants still underestimate AI's long-run deflationary effect on knowledge work.
More from The Analyst →This Week's Edition
13 November 2026
14 articles
Related Articles
Related Articles
More Stories
© 2026 Cedar & Bloom. All rights reserved.